EMA Publishes New Guidance for Qualified Person's Declaration on GMP Compliance of API - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA Publishes New Guidance for Qualified Person's Declaration on GMP Compliance of API


EMA has published a new guidance template for the qualified person’s declaration concerning GMP compliance of API manufacture.

The QP declaration template provides the basis for demonstrating compliance of the API manufacture with GMP requirements and ensures that the manufacturer has sufficient knowledge on the supply chain.

The objective of this guidance and the QP declaration template is to emphasize the importance of providing a valid declaration, to harmonize the format for the declaration, to forestall questions during assessment, and to enhance the efficiency of the regulatory process, including the timely processing of relevant regulatory submissions. While not mandatory, applicants are strongly encouraged to use the template to facilitate the validation of regulatory submissions and their review.

The QP declaration should be provided in support of applications for marketing authorizations, variation or renewal of a medicinal product(s) authorized in the Community, using EU or national procedures within the scope of the respective Directives.

QP declarations are required from each EEA finished-product manufacturing site and/or from each site of importation/batch certification. A single declaration from one QP from one of the registered finished product or batch-release sites, however, may be sufficient, if its basis is satisfactorily described and supported by technical agreements between these sites.

Source: EMA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here